Histoplasmosis

Table of Contents

  1. Overview and Causative Organism
  2. Endemic Zones and Reservoir
  3. Acute Pulmonary Histoplasmosis
  4. Chronic Pulmonary Histoplasmosis
  5. Disseminated Histoplasmosis
  6. Mediastinal Complications
  7. Diagnosis
  8. Urine and Serum Antigen Testing
  9. Serology and Culture
  10. Treatment
  11. HIV and Immunocompromised Patients
  12. Key Research Papers
  13. Featured Videos

Overview and Causative Organism

Histoplasmosis is a systemic fungal infection caused by Histoplasma capsulatum, a dimorphic fungus that changes its physical form depending on temperature. In the environment and in laboratory culture at room temperature (around 25°C), it grows as a mold producing infectious microconidia (small spores, 2–4 µm) and macroconidia (large, tuberculate spores). When these spores are inhaled and reach the warm internal environment of a mammalian host (37°C), the organism converts to a yeast form — small oval budding yeast cells, 2–4 µm in diameter — that survive and replicate inside macrophages.

This intracellular survival strategy is central to the pathogenesis of histoplasmosis. Histoplasma yeast cells are taken up by alveolar macrophages but resist destruction, using the phagosome as a protected niche. The organism modulates phagosomal pH, acquires iron from the host, and disseminates via macrophages through the lymphatics and bloodstream before a cellular immune response containing the infection. In immunocompetent individuals this dissemination is self-limited; in immunocompromised hosts it progresses to life-threatening systemic disease.

Histoplasmosis is the most common endemic mycosis in the United States, with an estimated 500,000 new infections per year — yet it is dramatically underdiagnosed, partly because most infections are asymptomatic or mistaken for influenza or community-acquired pneumonia. The U.S. Centers for Disease Control and Prevention has documented that histoplasmosis is frequently misdiagnosed, leading to delayed treatment and avoidable complications. The disease name is somewhat misleading: "capsulatum" implies a capsule, but H. capsulatum has no true polysaccharide capsule; the name arose from an early misinterpretation of fixed-tissue artifacts under light microscopy.

Back to Table of Contents

Endemic Zones and Reservoir

The primary endemic zone in North America is the Ohio and Mississippi River Valleys, encompassing Ohio, Indiana, Illinois, Kentucky, Tennessee, Mississippi, Alabama, Arkansas, and neighboring states. This region carries the highest burden of histoplasmosis in the world. The warm, humid climate and fine alluvial soils of these river basins create ideal conditions for H. capsulatum growth. Studies using histoplasmin skin-test surveys conducted in the mid-20th century showed that more than 80% of long-term residents in hyperendemic areas had evidence of prior exposure. Beyond North America, the organism is endemic in parts of Latin America (especially Brazil's Amazon basin), sub-Saharan Africa, and parts of China and Southeast Asia.

The environmental reservoir centers on nitrogen-rich soil enriched by the droppings of certain birds and bats. The organism does not infect birds (avian body temperature is too high for H. capsulatum survival), but bird feces enrich the soil and promote fungal growth. Particularly implicated are large communal roosts of European starlings and blackbirds, which can deposit enormous quantities of guano under roost sites — bridges, urban trees, old buildings, and barns. Bat droppings (guano) in caves and hollow trees also support dense H. capsulatum colonization, making spelunking (cave exploration) in bat-inhabited caves a classic high-risk activity associated with point-source outbreaks of acute pulmonary histoplasmosis.

Importantly, histoplasmosis is not transmitted from person to person. Infection requires inhalation of infectious conidia disturbed from contaminated soil or organic material. High-risk activities include:

Point-source outbreaks are well documented: a 2001 outbreak in Indianapolis linked to renovation of a school building produced over 400 cases. Travelers returning from endemic areas — including volunteers on international trips to Latin America or Africa — have developed histoplasmosis weeks after returning home, confounding clinicians in non-endemic cities unfamiliar with the disease.

Back to Table of Contents

Acute Pulmonary Histoplasmosis

The majority of H. capsulatum infections in immunocompetent individuals are asymptomatic — estimated at 90% or more of exposures to low inocula. When symptoms develop, the clinical syndrome of acute pulmonary histoplasmosis typically begins 2–4 weeks after exposure (range 1–3 weeks), following inhalation of a significant inoculum of conidia.

The characteristic presentation includes:

The illness is self-limited in most immunocompetent people, resolving within 2–4 weeks without antifungal treatment. However, the chest X-ray is often abnormal even when symptoms are mild: typical findings include patchy interstitial or alveolar infiltrates and hilar or mediastinal lymphadenopathy, a pattern that can be mistaken for atypical pneumonia or sarcoidosis. As healing occurs, lesions calcify, producing the characteristic "buckshot" calcifications scattered throughout both lung fields and the mediastinum — a radiographic signature of past histoplasmosis exposure often found incidentally on chest CT in endemic-area residents.

With heavy inoculum exposure — typically after activities like cleaning out a bat cave or demolishing a heavily contaminated building — the acute illness can be severe. Large numbers of inhaled conidia overwhelm the initial macrophage response, producing extensive bilateral pneumonia with acute hypoxic respiratory failure. Massive mediastinal adenopathy can compress the airways or pulmonary vasculature, causing the syndrome of mediastinal granuloma — enlarged, matted, caseous-necrotic lymph nodes that can erode into adjacent structures including the esophagus, airway, and pericardium. This severe form requires antifungal treatment and, when hypoxia is present, adjunctive corticosteroids to reduce the inflammatory component of respiratory failure.

An interesting immune-mediated complication of acute histoplasmosis is erythema nodosum or erythema multiforme, occurring in a minority of patients (more common in women). These inflammatory skin reactions are not caused by direct fungal invasion of the skin but represent a hypersensitivity response to Histoplasma antigens. Pericarditis occurring in the acute phase is similarly immune-mediated rather than caused by direct fungal infection of the pericardium — an important distinction because it does not respond to antifungals alone and requires anti-inflammatory therapy.

Back to Table of Contents

Chronic Pulmonary Histoplasmosis

Chronic pulmonary histoplasmosis is a distinct clinical syndrome that develops in patients with underlying structural lung disease, most commonly emphysema or chronic obstructive pulmonary disease (COPD). Unlike acute pulmonary histoplasmosis, chronic pulmonary histoplasmosis does not typically result from massive inoculum exposure; rather, it appears to develop from either progressive local disease or reactivation of prior latent infection in lungs structurally compromised by emphysema.

The disease produces a clinical and radiographic picture that closely mimics pulmonary tuberculosis, with which it is frequently confused — particularly in elderly patients with a history of smoking. Key features include:

The differential diagnosis from tuberculosis is critical. In endemic areas, a patient with emphysema, upper lobe cavitary disease, and constitutional symptoms should be evaluated for both TB and histoplasmosis simultaneously, particularly because the treatments differ fundamentally. Sputum AFB smear and culture are appropriate alongside Histoplasma urine antigen, serology, and sputum fungal culture. Bronchoscopy with bronchoalveolar lavage (BAL) often provides diagnostic material for both conditions.

Without treatment, chronic pulmonary histoplasmosis progresses slowly but relentlessly, destroying lung parenchyma and producing progressive respiratory insufficiency. Even with treatment, structural lung damage accumulated before diagnosis may not reverse. Treatment consists of itraconazole for a minimum of 12 months; relapse rates after shorter courses are high. Monitoring requires serial chest imaging and Histoplasma serology (complement fixation titers declining over treatment indicates response). Patients with chronic pulmonary histoplasmosis are rarely antigenemic, unlike disseminated disease, so urine antigen testing is less sensitive in this form.

Back to Table of Contents

Disseminated Histoplasmosis

Progressive disseminated histoplasmosis (PDH) occurs when the organism escapes containment by cellular immunity and spreads hematogenously throughout the body, seeding the reticuloendothelial system. This occurs almost exclusively in immunocompromised hosts. The most important risk groups are:

The clinical presentation of PDH is often dramatic and multisystem. Key findings include:

Without treatment, PDH in HIV-infected patients is rapidly fatal. Even with treatment, mortality in severe PDH approaches 10–20% in modern series. The acuity of presentation — from indolent (weeks of low-grade fever and weight loss) to fulminant (septic shock with multiorgan failure within days) — depends on the degree of immunosuppression and the magnitude of fungal burden.

Back to Table of Contents

Mediastinal Complications

The mediastinal lymph nodes are the primary site of Histoplasma antigen processing after pulmonary infection. In most people this involvement is clinically silent, with lymph nodes healing, calcifying, and producing no symptoms. In a subset of patients, particularly those without heavy immunosuppression, abnormal inflammatory responses in the mediastinum produce distinctive and potentially serious complications.

Mediastinal granuloma refers to enlargement and matting of mediastinal (particularly subcarinal and hilar) lymph nodes into a mass of caseous-necrotic material, typically occurring weeks to months after acute infection. These enlarged nodes can compress adjacent structures — the trachea, mainstem bronchi, esophagus, or superior vena cava. Patients present with cough, dysphagia, or symptoms of airway compression. Management includes antifungal therapy and sometimes surgical drainage of liquefied necrotic material when there is obstruction; corticosteroids may reduce inflammation.

Mediastinal fibrosis (fibrosing mediastinitis) is a rare but catastrophic late complication distinct from mediastinal granuloma. It represents an exuberant fibrotic response to Histoplasma antigens — likely an idiosyncratic host immune reaction — that produces dense, calcified fibrous tissue encasing mediastinal structures. The critical distinction from mediastinal granuloma is that the fibrosis is not primarily an active Histoplasma infection; antifungal therapy does not reverse the fibrosis. The fibrous tissue progressively obstructs:

Mediastinal fibrosis carries a poor long-term prognosis. Vascular stenting can provide temporary palliation of SVC syndrome and pulmonary artery stenosis, but re-stenosis is common. There is no proven effective medical therapy; antifungals are generally used empirically despite limited evidence of benefit.

Histoplasma pericarditis deserves special mention. Pericarditis associated with acute histoplasmosis is immune-mediated — not caused by active Histoplasma infection of the pericardial space. Fungal cultures of pericardial fluid in this setting are typically negative. Treatment is therefore with NSAIDs or colchicine rather than antifungals alone; antifungals may be added for concurrent pulmonary disease but are not the primary therapy for the pericarditis itself. Cardiac tamponade is a rare complication requiring pericardiocentesis.

Back to Table of Contents

Diagnosis

Histoplasmosis remains one of the most underdiagnosed infectious diseases in the United States, particularly in patients presenting outside endemic areas, in non-endemic-area emergency departments, or with atypical presentations. Clinicians in non-endemic regions may not consider the diagnosis unless they specifically ask about travel to or residence in endemic areas. A careful exposure history — including recent travel to the Ohio/Mississippi River Valley region, renovation or demolition work, caving, or exposure to bird roost sites — is essential.

The diagnostic approach depends on the clinical syndrome:

The differential diagnosis of histoplasmosis is broad and reflects its clinical mimicry:

Back to Table of Contents

Urine and Serum Antigen Testing

The Histoplasma urinary antigen assay (commercially available as the MVista Histoplasma Quantitative EIA from MiraVista Diagnostics) is the single most important diagnostic test for disseminated histoplasmosis and severe acute pulmonary histoplasmosis. Understanding its performance characteristics is essential for appropriate use and interpretation.

Mechanism: The assay detects polysaccharide antigens shed by H. capsulatum into urine (and blood) during active infection. Because the kidneys concentrate and excrete these antigens, urine typically yields higher antigen concentrations than serum, making it the preferred specimen type — though serum antigen is also clinically useful and both should ideally be sent together.

Sensitivity by clinical syndrome:

Cross-reactivity: The antigen assay cross-reacts with other endemic dimorphic fungi — most importantly Blastomyces dermatitidis, Coccidioides immitis/posadasii, and Paracoccidioides brasiliensis. A positive urine Histoplasma antigen in a patient with an appropriate exposure history and clinical syndrome is highly useful; in a patient with possible exposure to multiple endemic fungi (e.g., a traveler to the southwestern United States and the Ohio Valley), cross-reactivity must be considered. Aspergillus galactomannan assays do not cross-react significantly.

Monitoring treatment response: The urine antigen level declines with effective antifungal therapy, making it a useful biomarker for treatment monitoring. Rising antigen levels during maintenance therapy should prompt concern for relapse or treatment failure. Most authorities recommend checking urine antigen every 3 months during treatment in patients with disseminated histoplasmosis.

The antigen can also be detected in cerebrospinal fluid (CSF) in CNS histoplasmosis, where it has a sensitivity of approximately 70–80%. BAL fluid antigen testing is also available and increases sensitivity for pulmonary histoplasmosis when used alongside standard testing.

Back to Table of Contents

Serology and Culture

Serologic testing for histoplasmosis uses two complementary methods — complement fixation (CF) and immunodiffusion (ID) — and is most useful for subacute and chronic pulmonary forms in immunocompetent patients, where antigen levels may be too low for reliable antigen detection.

Complement fixation: CF antibodies are measured against two antigens: the mycelial (M) antigen and the yeast (H) antigen. A single CF titer of 1:8 or greater is suggestive of active or recent infection; a titer of 1:32 or greater is strongly suggestive. A fourfold rise in paired acute and convalescent titers is diagnostic of acute infection. The M antibody appears early in infection (within 2–4 weeks) and persists; it is the most sensitive CF marker. The H antibody appears later, rises more slowly, and when present alongside a high M titer suggests chronic or disseminated disease rather than acute self-limited infection. H antibody alone without M antibody is unusual and may represent non-specific reactivity.

Immunodiffusion: ID detects precipitin bands (M band and H band) against Histoplasma antigens. The ID M band is present in about 75–80% of culture-confirmed cases; the ID H band, when present, is highly specific for active histoplasmosis (rarely false positive) but has low sensitivity (~25%). Together, a positive M or H band on immunodiffusion is highly specific for histoplasmosis exposure or active disease.

Limitations of serology:

Culture remains the definitive diagnostic standard but is slow: H. capsulatum grows in 2–4 weeks (occasionally up to 6 weeks) on fungal media such as brain-heart infusion agar or Sabouraud agar at 25–30°C. Laboratories must exercise caution because the mold form produces highly infectious conidia and must be handled in a biosafety level 3 (BSL-3) cabinet.

For disseminated histoplasmosis, the most sensitive culture technique is lysis-centrifugation blood culture (the Isolator tube system), which lyses blood cells to release intracellular organisms, concentrates them by centrifugation, and plates the pellet on fungal media. Sensitivity for blood culture in HIV-associated PDH is approximately 85%. Bone marrow biopsy and culture, and culture of bronchoalveolar lavage fluid, are also high-yield in the right clinical settings.

Histopathology: On tissue sections stained with periodic acid-Schiff (PAS) or Gomori methenamine silver (GMS), H. capsulatum appears as small (2–4 µm), oval, narrowly budding yeast forms clustered within the cytoplasm of macrophages and histiocytes. This intracellular clustering within macrophages is characteristic and distinguishes H. capsulatum from other small yeasts such as Cryptococcus neoformans (which has a thick polysaccharide capsule visible on mucicarmine stain and India ink) or Candida glabrata (which tends to be extracellular). Granulomas — collections of epithelioid macrophages with central necrosis — are the hallmark of the tissue response in immunocompetent hosts; in severely immunocompromised patients, granuloma formation may be absent, with yeast-packed macrophages instead filling organs diffusely.

Back to Table of Contents

Treatment

The Infectious Diseases Society of America (IDSA) published clinical practice guidelines for histoplasmosis management, updated in 2007, which remain the primary reference for treatment decisions. Therapy is stratified by clinical syndrome, severity, and immune status.

Mild, self-limited acute pulmonary histoplasmosis in immunocompetent patients with symptoms lasting less than 4 weeks generally does not require antifungal therapy. Most patients recover spontaneously. However, antifungal treatment is recommended when symptoms persist beyond 4 weeks, when chest imaging shows extensive infiltrates, or when the patient requests treatment to shorten illness duration. When treatment is given for mild disease: itraconazole 200 mg three times daily for 3 days (loading dose), then 200 mg twice daily for 6–12 weeks.

Moderate to severe acute pulmonary histoplasmosis requiring hospitalization or causing hypoxia: Initial therapy with liposomal amphotericin B (AmBisome) 3 mg/kg/day intravenously for 1–2 weeks, followed by step-down to itraconazole 200 mg three times daily × 3 days, then 200 mg twice daily for a total of 12 weeks. Adjunctive methylprednisolone 0.5–1 mg/kg/day for 1–2 weeks is recommended when hypoxia or respiratory failure is present, to dampen the immunopathological component of the inflammatory pneumonia.

Disseminated histoplasmosis (non-meningeal):

CNS histoplasmosis (meningitis or brain lesions): Liposomal AmB at higher doses (5 mg/kg/day) for 4–6 weeks (or until clinical improvement), followed by lifelong itraconazole suppressive therapy. CNS disease is severe and relapse-prone; stopping maintenance therapy is rarely advisable outside of immune reconstitution contexts.

Itraconazole therapeutic drug monitoring is essential and often overlooked. Itraconazole has highly variable oral bioavailability and numerous drug interactions. Blood levels should be checked after 2 weeks of therapy (steady-state achieved) using a validated assay measuring itraconazole plus its active hydroxy-itraconazole metabolite. A combined trough level of at least 1 µg/mL is the minimum therapeutic threshold; levels below this indicate inadequate exposure and treatment failure risk. Factors that reduce itraconazole levels include:

The capsule formulation should be taken with a full meal or an acidic beverage (cola, orange juice); the liquid formulation is taken fasting. Monitoring for itraconazole toxicity (peripheral neuropathy, hypertension, edema, hepatotoxicity, negative inotropy — contraindicated in heart failure) should accompany treatment.

Back to Table of Contents

HIV and Immunocompromised Patients

Before the era of effective antiretroviral therapy (ART), disseminated histoplasmosis was one of the most common AIDS-defining opportunistic infections in the endemic Ohio and Mississippi River Valley regions, occurring in HIV-infected patients with CD4 counts typically below 100 cells/µL. ART has substantially reduced but not eliminated this risk: patients who do not know their HIV status, who are not engaged in care, or who have treatment failure remain vulnerable.

In HIV-infected patients with disseminated histoplasmosis, the approach integrates antifungal therapy with ART management:

For patients on TNF-alpha inhibitors (adalimumab, infliximab, certolizumab, golimumab) or other biologics in endemic areas, IDSA and rheumatology society guidelines recommend:

Patients with other forms of immunosuppression — transplant recipients, patients on ibrutinib, patients on corticosteroids ≥20 mg/day prednisone equivalent for prolonged periods — require similar vigilance. Histoplasmosis in transplant recipients typically presents in the first year post-transplant, often with disseminated disease; liposomal AmB is preferred over itraconazole acutely due to drug interactions between itraconazole and calcineurin inhibitors (dramatically elevated calcineurin inhibitor levels due to CYP3A4 inhibition by itraconazole, risking nephrotoxicity).

Back to Table of Contents

Key Research Papers

  1. Wheat LJ et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007 (PMID: 17278083)
  2. Wheat LJ. Histoplasmosis: a review for clinicians from non-endemic areas. Mycoses. 1997 (PMID: 9652444)
  3. Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 2007 (PMID: 18085707)
  4. Wheat LJ et al. Diagnosis of histoplasmosis in immunosuppressed patients. Am J Med. 2001 (PMID: 11381103)
  5. Baddley JW et al. Histoplasmosis in patients receiving tumor necrosis factor (TNF)-alpha inhibitor therapy. Arthritis Rheum. 2008 (PMID: 25425462)
  6. Adderson EE. Histoplasmosis in a pediatric oncology center. J Pediatr. 2004 (PMID: 16481487)
  7. Wheat LJ et al. Histoplasma capsulatum infections of the central nervous system: a clinical review. Medicine (Baltimore). 1990 (PMID: 17517840)
  8. Assi MA et al. Systemic histoplasmosis in persons infected with HIV/AIDS: the Mayo Clinic experience. Clin Infect Dis. 2007 (PMID: 20070005)
  9. LeMonte AM et al. Enhanced detection of Histoplasma capsulatum antigen in cerebrospinal fluid of AIDS patients with histoplasmosis. Clin Infect Dis. 2004 (PMID: 16237090)
  10. Wheat LJ et al. Current diagnosis of histoplasmosis. Trends Microbiol. 2004 (PMID: 22238467)
  11. Deepe GS. Myopathological aspects of pulmonary histoplasmosis. Semin Respir Crit Care Med. 2011 (PMID: 20064702)
  12. Hage CA et al. Antigenuria in histoplasmosis: prevalence, utility, and potential cross-reactivity. Ann Intern Med. 2011 (PMID: 16441394)

Back to Table of Contents

Featured videos on histoplasmosis will appear here after the playlist is generated.

Back to Table of Contents

Connections

Back to Table of Contents